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Background: Hyperlipidemia, a metabolic disorder of lipids, is a well known risk factor of cardiovascular events and
metabolic syndrome. In this study, the in vivo lipid-lowering activity of the triterpene (Methyl-3β-hydroxylanosta-9,
24-dien-21-oate), isolated from the stem bark of Protorhus longifolia, in high fat diet (HFD)-induced hyperlipidemic rats
was investigated.
Methods: Structure of the isolated compound was established and confirmed based on spectral (NMR, HRMS, IR) data
analysis. Rats were divided into two groups; normal group (fed the normal commercial rats’ chow) and the HFD group.
After 21 days of experimental period on their respective diets, the HFD rats were sub-divided into 4 groups of six rats
per group. Two of the HFD groups were orally treated with the triterpene (100 and 200 mg/kg body weight) for 15 days.
At the end of the experimental periods, the rats were sacrificed and blood samples were collected for biochemical
assays.
Results: The results show that there were significant increases in total serum cholesterol (TC, 15.72 mmol/L) and
low-density lipoprotein cholesterol (LDL-c, 7.41 mmol/L) with a reduction in high-density lipoprotein cholesterol
(HDL-c, 14.75 mmol/L) in HFD-induced hyperlipidemic rats after 21 days. Oral administration of the triterpene (100 mg/
kg.bw and 200 mg/kg.bw) for a period of 15 days resulted in significant lowering of the levels of TC (7.51 mmol/L) and
LDL-c (4.46 mmol/L) with an increase in HDL-c (47.3 mmol/L) in HFD-induced hyperlipidemic rats. Significant decrease
in atherogenic index and coronary risk index by the triterpene was observed in HFD-induced hyperlipidemic rats.
Conclusions: The triterpene could effectively reduce or control the amount of serum cholesterol and LDL. It is
apparent that the compound could contribute to new formulation with significant hypolipidemic effects.
Keywords: Hyperlipidemia, High fat diet, TriterpeneBackground
Hyperlipidemia, a disorder of lipid metabolism character-
ized by elevated levels of lipids circulating in the blood,
has now become a global concern. It is considered as one
of the five leading causes of death in the world [1]. Its
prevalence is greatly influenced by adaptation of sedentary
lifestyle and an increase in consumption of a high-fat diet
[2]. Hyperlipidemia is strongly linked to the development
of cardiovascular events and metabolic syndrome diseases* Correspondence: OpokuA@unizulu.ac.za
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unless otherwise stated.[3]. Thus, regulation of blood lipid levels is vital in the pre-
vention and treatment of hyperlipidemia and its related
diseases.
Currently, a number of anti-hyperlipidemic agents have
been introduced for the treatment of hyperlipidemia.
One of the most widely used anti-hyperlipidemic agents
at present is lovastatin, which reportedly slows down
the body’s ability to make cholesterol by targeting hepa-
tocytes and inhibiting HMG-CoA reductase; the en-
zyme that converts HMG-CoA into mevalonic acid, a
cholesterol precursor [4]. However, this drug is associ-
ated with undesirable side effects (such as myositis and
rhabdomyolysis, elevated CK levels, muscle weakness,al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 13C-NMR data and significant 1H-NMR data of the
compound
Position δC (ppm) Type δH (ppm)
1 30.4 CH2
2 23.9 CH2
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http://www.lipidworld.com/content/13/1/131and muscle cramps) in humans [5,6]. Such adverse ef-
fects of the current anti-hyperlipidemic drugs stimulate
the search for alternative medicine with improved effi-
cacy and safety profile.
Medicinal plants have always been rich sources of bio-
logically active compounds vital to human health. Thus a
search for new lead molecules with anti-hyperlipidemic
properties from plants could be a useful strategy. Anti-
hyperlipidemic activity of a number of medicinal plants
and/or plant-derived bioactive compounds has been re-
ported. Such studies include the hypolipidemic activity
of Pandanus tectorius fruit extract [7], Coriolus versicolor
[6] and 2, 4, 6-Trihydroxyacetophenone isolated from
Myrciamultiflora [8].
Stem bark of Protorhus longifolia (Benrh.) Engl. (Ana-
cardiaceae), a tree indigenous to Southern Africa, is one
of the plants commonly used by Zulu traditional healers
in the management of blood-clotting related diseases.
Antimicrobial activity of the leaf extracts of the plant
has been reported [9]. Cytotoxic and anti-platelet aggre-
gation activity of the crude extracts and two lanosteryl
triterpenes from the stem bark of the plant have recently
been reported [10,11]. A growing body of evidence sup-
port plant-derived triterpenes as new targets for drug
development due to their diverse potential pharmaco-
logical activities. The in vitro anti-hyperlipidemic activity
of methyl-3β-hydroxylanosta-9,24-dien-21-oate isolated
from Protorhus longifolia has been observed in our la-
boratory (unpublished data). The present study reports
on the in vivo hypolipidemic activity of the triterpene
from Protorhus longifolia in a high fat diet (HFD)-induced
hyperlipidemia in rats.
Results
The structure of the isolated compound (Figure 1) was
established and confirmed using 1H and 13C-NMR. The
isolated compound (Methyl-3β-hydroxylanosta-9,24-dien-
21-oate, KE1) was obtained as white crystals, > 95% pure,
mp 204-205°C, IR (KBr) vmax = 3469, 1683 cm
−1. SeeFigure 1 Chemical structure of methyl-3β-hydroxylanosta-9,
24-dien-21-oate (KE1).Table 1 for 1H and 13C NMR data. The data suggested the
molecular formula C31H50O3, calculated 470.736. Spectra
of the compound are presented in Additional file 1.
The effects of the normal diet (ND) and HFD fortified
with different concentrations of KE1 or lovastatin on the
body weight, food conversion, food efficiency ratio, liver
weights and adiposity level in HFD fed rats over the
period of study are shown in Table 2. The control group
of rats subjected to ND for 21 and 36 days showed sig-
nificant increase (p < 0.05) in the body weight by 12.12%
and 41.93%, respectively. It is apparent that the rats were
gaining weight over the 36 days of study. The control




24 125.6 CH 5.21 (1H, t)
25 136.4 C
26 17.4 CH3 1.61 (3H, s)
27 25.8 CH3 1.65 (3H, s)
28 21.9 CH3 1.21 (3H, s)
29 27.4 CH3 0.90 (3H, s)
30 22.1 CH3 1.16 (3H,s)
-OCH3 59.8 3.85 (3H, s)
13C-NMR- carbon-13 NMR, 1H-NMR- Hydrogen-1(proton) NMR.
Table 2 Effect of the triterpene on percentage weight change, food conversion, food efficiency ratio, liver weights and
adiposity level in HFD rats
Group Weight change (%) Food Conversion Food Efficiency Ratio Liver (g) Adiposity level × 1004
ND (after 21 days) 12.12 ± 0.44*** 0.82 ± 0.07 1.23 ± 0.14*** 3.37 ± 0.17 1.17 ± 0.03
(after 36 days) 41.93 ± 6.29 0.21 ± 0.02 4.91 ± 0.47 2.97 ± 0.03 1.17 ± 0.04
HFD (after 21 days) 6.18 ± 1.09 1.30 ± 0.35 0.96 ± 0.25 4.67 ± 0.06 1.02 ± 0.01
(after 36 days) 13.66 ± 1.77*** 0.62 ± 0.05 1.53 ± 0.13*** 5.21 ± 0.29*** 1.06 ± 0.01*
HFD/KE1 (100 mg/kg) 6.01 ± 1.57 0.75 ± 0.14 1.12 ± 0.40 4.68 ± 0.21 1.04 ± 0.01
HFD/KE1 (200 mg/kg) 10.04 ± 2.72 0.19 ± 0.02 4.43 ± 1.03*** 5.73 ± 0.18 1.08 ± 0.01
HFD/lovastatin (10 mg/kg) 3.74 ± 1.20** 2.17 ± 0.59** 0.69 ± 0.14 4.75 ± 0.14 1.03 ± 0.01
All values are expressed as mean ± SEM, (n = 4); *p < 0.05, **p < 0.01, ***p < 0.001 compared to the HFD 36 days.
*p < 0.05, **p < 0.01, ***p < 0.001 compared to the ND 36 days.
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http://www.lipidworld.com/content/13/1/131increase in body weight (13.66%), food conversion and
liver weight but a reduction in food efficiency ratio and
adiposity level compared to control group of rats sub-
jected to ND for 21 days. Like lovastatin, a standard hy-
polipidemic drug, treatment with the triterpene at
100 mg/kg.bw, according to HFD (after 36 days), indi-
cated a potential reduction in percentage body weight,
food efficiency ratio, liver weights, adiposity level and an
increase in food conversion in rats.
Table 3 presents the results on the effects of the HFD
and HFD fortified with different concentrations of KE1
and lovastatin on total cholesterol and triacylglyceride
levels. The hyperlipidemia group of rats subjected to
HFD for 21 and 36 days indicated an increase (p < 0.001)
in total cholesterol and LDL with increases in HDL
levels. A statistically significant reduction (p < 0.001) in
total cholesterol and LDL accompanied by a significant
increase in HDL was observed in the animals fed the
HFD fortified with the triterpene at 100 and 200 mg/kg.
bw according to HFD (after 36 days). There were no sta-
tistically significant changes observed in triacylglyceride
and VLDL levels compared to normal group of rats fed
ND for 36 days.
The effect of the triterpene on atherogenic index and
coronary risk index in hyperlipidemic rats was also eval-
uated and the results are given in Figure 2. The triter-
pene at different concentrations (100 and 200 mg/kg.bw)
exhibited a significant reduction in atherogenic indexTable 3 Effect of the triterpene on serum lipids and lipoprote
Group Total cholesterol Triglyceri
ND (after 21 days) 1.38 ± 0.12 0.68 ± 0.11
(after 36 days) 1.83 ± 0.24 0.79 ± 0.06
HFD (after 21 days) 15.72 ± 1.10 1.29 ± 0.54
(after 36 days) 49.52 ± 4.83*** 1.41 ± 0.35
HFD/KE1 (100 mg/kg) 34.24 ± 1.50*** 1.93 ± 0.15
HFD/KE1 (200 mg/kg) 7.51 ± 0.97*** 0.46 ± 0.05
HFD/lovastatin (10 mg/kg) 38.66 ± 3.25* 0.77 ± 0.13
All values are expressed as mean ± SEM, (n = 4); *p < 0.05, **p < 0.01 compared to thand coronary risk index in HFD-induced hyperlipidemic
animals for 36 days. Similar results were also observed
in the rats fed HFD fortified with lovastatin.
The results for liver enzymes (ALP, ALT and AST)
levels along with histopathological changes of the rat
liver following treatment with HFD fortified with the tri-
terpene are presented in Table 4 and Figure 3, respect-
ively. Reduced levels of the liver enzymes were observed
in rats treated with HFD fortified with the triterpene
reaching levels similar to those in the ND group. Liver
tissue from the rat treated with the triterpene depicted a
lower accumulation of lipid droplets as compared to the
liver of the rat fed HFD only in which numerous fat
droplets and severe vascular changes with displaced nu-
clei were evident.
Discussion
The structure of the isolated compound (Figure 1) was
established and confirmed on the basis of 1H and 13C
NMR data analysis. The 1H-NMR of the compound
followed the same triterpenoid pattern observed in 3β-
hydroxylanosta-9,24-dien-21-oic acid [11], with a large
clusters of signals of CH3, CH2 and CH between δH 2.5
and 0.8. The 13C-NMR of this compound also resembled
that of 3β-hydroxylanosta-9,24-dien-21-oic acid, with
five quaternary carbon atoms, and the presence of four
olefinic carbon atoms between 145–118 ppm confirming
the lanosteryl skeletal structure. The presence of an esterins levels (mmol/L) in HFD-induced hyperlipidemia in rats
de VLDL-c LDL-c HDL-c
0.14 ± 0.04 0.11 ± 0.04 1.14 ± 0.90
0.26 ± 0.18 0.10 ± 0.02 1.86 ± 0.07
0.28 ± 0.22 7.41 ± 0.56** 14.75 ± 0.19***
0.28 ± 0.14 10.72 ± 0.94*** 6.17 ± 0.16***
0.39 ± 0.05 5.85 ± 0.81*** 30.39 ± 0.92***
0.09 ± 0.01 4.46 ± 0.82*** 47.30 ± 0.9***
0.15 ± 0.03 12.97 ± 0.59 29.13 ± 0.68***
e HFD 36 days; *p < 0.05, **p < 0.01, ***p < 0.001 compared to the ND 36 days.
Figure 2 Effect of the triterpene on atherogenic index (AI) and
coronary risk index (CRI) in HFD-induced hyperlipidemia in rats.
All values are expressed as mean ± SEM, (n = 4); ***p < 0.001 compared
to the HFD 36 days; ***p < 0.001 compared to the ND 36 days.
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at δC 181.5 assisted in suggesting the methyl ester of 3β-
hydroxylanosta-9,24-dien-21-oic acid. Detailed assignment
of the 13C-NMR and significant 1H-NMR of the com-
pound are presented in Table 1. The absorption bands
for carbonyl (1683 cm−1), and hydroxyl (3469 cm−1)
functional groups observed on IR spectrum also further
assisted in confirming the NMR structure.
Consumption of a high-lipid diet may create diverse
patterns of hyperlipidemia. Abnormalities of lipid metab-
olism are associated with cardiac diseases, obesity and
their associated disorders [12]. Thus regulation of dys-
lipidemia is crucial for the prevention and treatment of
cardiovascular events [13,14].
In this study, the hypolipidemic activity of the triterpene
from stem bark of P. longifolia was evaluated in the
HFD-induced hyperlipidemia in rats. The results ob-
tained from this study demonstrate that the triterpene
has anti-hyperlipidemic properties. The ability of the
HFD supplemented with the triterpene to significantly
(p < 0.001) lower serum TC and LDL-c levels while
increasing HDL-c levels (Table 3) suggested the hypo-
lipidemic activity of the compound. These results areTable 4 Effect of the triterpene on liver enzymes on HFD-indu
Group ALP (U/L)
ND (after 21 days) 73.00 ± 24.85
(after 36 days) 46.10 ± 11.94
HFD (after 21 days) 179.90 ± 34.38
(after 36 days) 249.00 ± 60.40**
HFD/KEM (100 mg/kg) 181.10 ± 25.53
HFD/KEM (200 mg/kg) 363.30 ± 53.23
HFD/lovastatin (10 mg/kg) 108.80 ± 35.03
All values are expressed as mean ± SEM, (n = 4); **p < 0.01, compared to the ND 36consistent with other literature reports on the hypolipid-
emic activity of plant-derived compounds. A triterpenoid
mixture (α, β-amyrin) from Protium heptaphyllum [15]
and lanostane triterpenoids from Prosthechea michuacana
[16] have been reported to exert their hypolipidemic ef-
fects through reduction of serum cholesterol and triglycer-
ide while increasing the levels of HDL-c. Consumption of
plant sterol and their esters has also been reported to not
only lower intestinal cholesterol absorption but decreased
blood levels of the atherogenic LDL-c as well [17,18].
Since HDL possesses many features that contribute to the
protection from atherosclerosis and related incidences
[19], hypolipidemic agents with the ability to also increase
serum levels of HDL-c are of great target.
The lower AI and CRI (Table 3) observed in this study
in HFD-induced hyperlipidemic rats following the 15 days
treatment with the triterpene suggested the cardiovascular
protective potential of the compound. The formation of
plaque in arteries, atherosclerosis, as a result of high
cholesterol and LDL-c in the blood can lead to serious
problems such as stroke, heart attack or even death
[20]. Significant reduction in AI and CRI were also re-
ported by Chaudhari et al. [12] using embelin extracted
from Embelia ribes and this is considered beneficial in
patients with atherosclerosis and obesity. The triterpen-
oid mixture from Protium heptaphyllum has also been
reported to significantly reduce the AI in HFD-induced
hyperlipidemia in rats [15]. It is apparent that the com-
pound exerts its therapeutic effect through reduction of
atherogenic cholesterol and triglyceride.
Prolonged consumption of high-fat diet increases syn-
thesis of TG and inhibit β-oxidation of fatty acids which
consequently leads to the accumulation of excess TG in
the liver [12,21]. The accumulation of the TG causes an
increase in liver weight and adipose tissues [12,22].
Interestingly, the triterpene from P. longifolia did not
only reduce body weight, but liver weight and adiposity
level (Table 2) in rats. The reduction in the liver en-
zymes activity (Table 4) and accumulation of fat droplets
(Figure 3) in the liver of HFD-induced hyperlipidemic
rats is indicative of the hepatoprotective effect of the tri-
terpene with low cytotoxicity. Elevated liver enzymesced hyperlipidemia in rats
ALT (U/L) AST (U/L)
45.90 ± 13.45 226.00 ± 95.57
51.90 ± 10.32 289.20 ± 68.95
78.20 ± 30.09 339.30 ± 138.06
83.80 ± 18.67 298.80 ± 55.34
42.30 ± 6.90 161.90 ± 52.22
48.80 ± 8.28 205.50 ± 37.12
44.11 ± 9.82 188.80 ± 52.76
days.
Figure 3 Histopathological changes (200x magnification) in liver of high fat diet induced hyperlipidemia after 15 days treatment with
the triterpene. I- liver tissue of the rat fed a normal diet; II- liver tissue of the rat fed a HFD; III- liver tissue of the triterpene (200 mg/kg.bw)
treated and HFD fed rat.
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liver [23]. Thus liver enzymes are the proper indicator of
normal function of the liver. A low cytotoxicity of the
triterpenes from P. longifolia on hepatic and kidney cells
has been reported [11].
Conclusion
The results obtained in this study show that the triterpene
(methyl-3β-hydroxylanosta-9,24-dien-21-oate) isolated
from Protorhus longifolia has a significant hypolipid-
emic activity in high fat diet fed rats. This is evidenced
by the reduction of serum TC and LDL-c, with an in-
creased HDL-c concentration in the HFD fed treated
groups. Significant reduction in AI and CRI by the tri-
terpene was observed and it can thus be considered
beneficial in reducing the risk of atherosclerosis. The
compound could effectively control the amount of
serum lipids and liver enzymes with lower toxicity. It is
apparent that the compound could contribute to new
formulation with significant hypolipidemic effects.
Methods
Plant material
Fresh stem barks of Protorhus longifolia (Benrh.) Engl.
were collected in March 2012 from Hlabisa, Kwa-ZuluNatal, South Africa. The plant (voucher specimen
number RA01UZ) was authenticated by Dr. N.R. Ntuli,
Department of Botany, University of Zululand. The plant
material was thoroughly washed with tap water and then
air dried. The air dried plant material was ground into
powder (2 mm mesh) and stored in sterile brown bottles
until use.
Extraction and isolation
The method of extraction and isolation of the triterpenes
from the stem bark of P. longifolia has been previously
described [11]. Briefly, the powdered plant material was
first defatted with n-hexane and then extracted (1:5 w/v)
with chloroform. The compounds were isolated from the
chloroform extract (13 g) using silica gel column chroma-
tography (24 × 700 mm; Silica gel 60; 0.063 - 0.2 mm;
70–230 mesh ASTM, Merck, Darmstadt, Germany).
The column was eluted stepwise with a mixture of n-
hexane and ethyl acetate (9:1–3:7) and 20 ml fractions
were serially collected. Thin layer chromatography
(TLC) (silica gel 60 TLC aluminium sheets 20 cm ×
20 cm, F254, Darmstadt, Germany) was used to analyse
the fractions. The combined fraction 14 was further
purified in ethyl acetate to afford the compound (KE1,
1.15 g). Melting point of the compound was determined
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Instruments supplies, Durban, South Africa). Spectro-
scopic data analysis, NMR (1H-1H, 13C-13C, in DMSO,
Bruker 600 MHz), HRMS (in DCM, Waters Synapt G2)
and infrared (IR) (Perkin-Elmer 100 FTIR) techniques
were used to establish and confirm structure. Chemical
shifts were expressed in δ (ppm).Animals
This study was approved by University of Zululand
Research Animal Ethics Committee (UZREC 171110–
030 Dept. 2013/23). Sprague–Dawley rats (180-220 g)
were collected from animal house in the Department
of Biochemistry, University of Zululand, South Africa.
Experimental procedures were conducted following
the guideline for care and supervision of experiments
on animals. The animals were housed in standard cages
and maintained at room temperature with 12:12-h light:
dark cycle. All rats had free access to drinking water and
standard rat feed in the experimental environment, for
1 week, before the experiment was conducted. Once the
animals had adapted to the environment, forty-two (42)
rats were divided into two groups; normal group (ND)
consisting of 12 rats and the high fat diet (HFD) group
consisting of 30 rats. After 21 days on their respective di-
ets, 6 rats per group were sacrificed and the remaining rats
of the HFD group were randomly divided into a total of
four (4) groups of six rats per group.Experimental design
1) Group 1: normal diet and vehicle throughout the
study
2) Group 2: high fat diet and vehicle throughout the
study
3) Group 3: was subdivided into two groups (A, B) and
received high fat diet and compound (100 and
200 mg/kg body weight, respectively), dissolved in
2% Tween 20
4) Group 4: high fat diet and lovastatin (10 mg/kg body
weight), dissolved in 2% Tween 20Induction of dyslipidemia in rats
The method previously described by Hor et al. [6] was
followed to evaluate the anti-hyperlipidemic activity of
the triterpene. Rats were made hyperlipidemia by feeding
a high fat diet [commercial rat chow (97.3%), Sunflower
oil (15%), bile salt (0.5%), cholesterol (5%), Thirmecil
(0.2%)]. This HFD preparation was pelleted (about 3 g
each) and fed daily to the rats for 36 days to induce
hyperlipidemia.Measurement of body weight and food intake
Body weight and food intake were recorded every other
day over the study period of 21 or 36 days. Percentage
weight change, food conversion (FC), and food efficiency
ratio (FER) were then calculated.
% weight change on day 21 or 36
¼ bodywt onday21or 36−bodywt onday1
bodywt onday1
 100
Foodconversion FCð Þ ¼ Food intake gð Þ
wt:gain gð Þ
Food efficiency ratio FERð Þ ¼ wt:gain gð Þ
Food intake gð Þ
Relative liver weight per 100g body weight of rat




Collection of blood samples and Liver for Lipid profile
determination
At the end of the experimental periods, the rats were
fasted for 8 hours, and then sacrificed by a blow to
the head and blood samples were collected by car-
diac puncture. The collected blood samples were
centrifuged at 3500 rpm for 10 minutes and the
serum collected for biochemical studies. The liver
was excised, weighed and stored in formalin for
histological studies.
Histology studies were carried out at the Vet Diagnostix
Laboratories (Pietermaritzburg, SA) by qualified patholo-
gist having no prior knowledge to which group they
belonged. The liver tissues were stained with haematoxylin
and eosin (H & E). This method allowed for unbiased de-
scription of the histological lesions which were present or
absent in the samples.
Biochemical assays
The serum samples were used for the estimation of total
cholesterol (TC), total triglyceride (TG), HDL-cholesterol
(HDL-c), AST, ALT and Alkaline phosphatase. Analysis
was done using the Cobas c 111 analyzer.
LDL-cholesterol (LDL-c) was estimated using Friedwald’s
equation [24]
LDL-c = [TC-(HDL-c + (TG/5)]
Other lipids parameters such as VLDL- cholesterol,
coronary risk index and atherogenic index (AI) were
calculated [12] as follows:
LDL-c = [TC-(HDL-c + (TG/5)]
VLDL-c = [TG – (HDL-c + LDL-C)]
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Coronary risk index (CRI) = TC/HDL-c (mg/dl)
Adiposity level ¼
" ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
Body wt gð Þ





Data was analyzed using one-way analysis of variance
(ANOVA) followed my Tukey-Kramer multiple com-
parison test using GraphPad InStat® version 3. The re-
sults are presented as mean ± standard error of the mean
(SEM). Values of p < 0.05 were considered significant.
Additional file
Additional file 1: A1 Spectra of KE1. Figure S1. IR spectrum of KE1.
Figure S2. 1H-NMR spectrum of KE1. Figure S3. 13C-NMR spectrum of KE1.
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